Abuse potential refers to the likelihood for a drug to be used in nonmedical situations for its positive psychoactive effects. PRA Health Sciences’ Early Development Services group offers expert services to measure abuse potential of investigational drugs by performing human abuse liability (HAL) studies, which are required for drugs that affect the central nervous system, drugs similar to known drugs with abuse potential, and drugs with positive psychoactive effects. This poster discusses what a HAL study is and the challenges posed to study teams and medical writers by the complexity and unique design of these Phase I clinical trials.
ECG Assessments During the Development of Oncology Compounds
Single-center oncology studies performed by dedicated PRA staff, combined with the High Precision QT approach of iCardiac, generates conclusive ECG…
Making Clinical Trial Recruitment More Efficient
Pharmacokinetic Charcateristic of Oral_Intranasal Morphine ARER
Extended-release (ER) opioid formulations are often targeted for misuse and abuse because they contain high amounts of opioid. An oral…